Comparative profile of tizanidine in the management of spasticity.
The therapeutic profile of a new antispastic drug cannot be defined solely on the basis of placebo-controlled studies. Its potential advantages must be evaluated in comparison with existing drugs. This review compares the efficacy and tolerability of tizanidine, a newer muscle relaxant, with that of baclofen and diazepam, the most widely used antispastic agents, for a variety of diagnoses and target symptoms associated with spasticity. More than 20 double-blind, comparative studies were conducted between 1977 and 1987. These included a total of 777 patients suffering from spasticity of various causes. The collected clinical data have been integrated into a combined analysis. Tizanidine emerges from this comparison as a valuable drug in the treatment of spasticity related to cerebral and spinal disorders.
CNS Department, Clinical Research & Development, Sandoz Pharma Ltd, Basel, Switzerland.
X
X
Lataste
M
M
Emre
C
C
Davis
L
L
Groves
D000203:Activities of Daily Living; D001418:Baclofen / Q000009:adverse effects / Q000627:therapeutic use; D003000:Clonidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003975:Diazepam / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D009125:Muscle Relaxants, Central / Q000009:adverse effects / Q000627:therapeutic use*; D009128:Muscle Spasticity / Q000188:drug therapy* / Q000503:physiopathology; D009129:Muscle Tonus / Q000187:drug effects
D009125:Muscle Relaxants, Central; C023754:tizanidine; D001418:Baclofen; D003000:Clonidine; D003975:Diazepam